IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company's next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal reasons. Dr. Tapolczay will continue to serve the company as Head of Strategy & Licensing, ensuring continuity in strategic development and with an immed
Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces the filing of two groundbreaking patents for tapinarof (VTAMA®), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a com
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value. Under the program, Conduit may repurchase shares from time to time through open market transactions or other methods in compliance with SEC Rule 10b-18. Purchases will be executed by The Benchmark Company, the Company's appointed broker, and w
Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces that it has entered into an additional license and use agreement (the "Additional Agreement") with Sarborg Limited ("Sarborg") to expand the scope of work on Conduit's acquired AstraZeneca assets, including AZD1656, AZD5658, and AZD5904. Under the agreement, Sarborg will apply its pr
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces that the United States Patent and Trademark Office (USPTO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent prote
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 19, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The Company has made significant progress with respect to confirmatory pre-clinical studies, clinical trial planning, formulation development, and intellectual
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq") Hearing Panel (the "Panel") and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1), 5450(b)(2&3)(C) and 5450(b)(2)(A), the Minimum Bid Price ("Bid Price"), Market Value of Publicly Held Shares ("MVPHS") and Market Value of Listed Securities ("MVLS") rules, respectively. On March 5, 2025, the Company received a written notification (the "Notice") from t
Collaboration reinforces Conduit's commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug developmentSarborg delivers a prototype AI-product to Conduit's Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company"), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg Limited. Further to the Company's previous announcement regarding the successful completion of Phase I, this next phase focuses on the prototype development of personal
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes.The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company"), is pleased to announce an agreement with Charles River Laboratories Inc ("Charles River")
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announces the repayment of its $600,000 promissory note (the "Note") to Nirland Limited ("Nirland") and provided an update on the conversion of its Senior Secured Promissory Note (the "Senior Note") with Nirland. On February 7, 2025, Conduit repaid the final balance of the Note in full, satisfying all obligations under the agreement. The Note, issued on October 28, 2024, had an original principal amount of $600,000, bore interest at a rate of 12% per annum, and was due to mature on October 31, 2025. In addition, as of February 10, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company's next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal reasons. Dr. Tapolczay will continue to serve the company as Head of Strategy & Licensing, ensuring continuity in strategic development and with an immed
Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces the filing of two groundbreaking patents for tapinarof (VTAMA®), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a com
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value. Under the program, Conduit may repurchase shares from time to time through open market transactions or other methods in compliance with SEC Rule 10b-18. Purchases will be executed by The Benchmark Company, the Company's appointed broker, and w
Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces that it has entered into an additional license and use agreement (the "Additional Agreement") with Sarborg Limited ("Sarborg") to expand the scope of work on Conduit's acquired AstraZeneca assets, including AZD1656, AZD5658, and AZD5904. Under the agreement, Sarborg will apply its pr
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces that the United States Patent and Trademark Office (USPTO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent prote
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 19, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The Company has made significant progress with respect to confirmatory pre-clinical studies, clinical trial planning, formulation development, and intellectual
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq") Hearing Panel (the "Panel") and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1), 5450(b)(2&3)(C) and 5450(b)(2)(A), the Minimum Bid Price ("Bid Price"), Market Value of Publicly Held Shares ("MVPHS") and Market Value of Listed Securities ("MVLS") rules, respectively. On March 5, 2025, the Company received a written notification (the "Notice") from t
Collaboration reinforces Conduit's commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug developmentSarborg delivers a prototype AI-product to Conduit's Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company"), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg Limited. Further to the Company's previous announcement regarding the successful completion of Phase I, this next phase focuses on the prototype development of personal
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes.The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company"), is pleased to announce an agreement with Charles River Laboratories Inc ("Charles River")
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announces the repayment of its $600,000 promissory note (the "Note") to Nirland Limited ("Nirland") and provided an update on the conversion of its Senior Secured Promissory Note (the "Senior Note") with Nirland. On February 7, 2025, Conduit repaid the final balance of the Note in full, satisfying all obligations under the agreement. The Note, issued on October 28, 2024, had an original principal amount of $600,000, bore interest at a rate of 12% per annum, and was due to mature on October 31, 2025. In addition, as of February 10, 2025
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13D/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
S-3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
PRE 14A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
8-K - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
SCHEDULE 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
8-K - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
8-K/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
8-K - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
10-K - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
424B5 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
8-K - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in
SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide